CXCL9, CXCL10 and CXCL11 have been previously shown to be effective in supporting an adequate antitumoral response in various cancers (55), although results in pancreatic cancer have been conflicting (56, 57). This evidence concerns the gene CXCL10 and familial pancreatic carcinoma.